GlassScriptPhysician profile
Hooman D Behravan
NPI 1255308904
$8,630.54
in general payments reported to CMS, 2019-2025
32 companies · $36.40 in 2025
The $36.40 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,143 · 2020: $468 · 2021: $496 · 2022: $581 · 2023: $623 · 2024: $283 · 2025: $36.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $5,615.60 | 2019 | |
| Scilex Pharmaceuticals INC. | $1,175.46 | 2019-2024 | Ztlido |
| Collegium Pharmaceutical, INC. | $251.30 | 2019-2023 | Belbuca |
| Alkermes, INC. | $156.70 | 2022-2024 | Lybalvi, Aristada |
| Merz Pharmaceuticals, LLC | $156.65 | 2021-2025 | Xeomin |
| Allergan, INC. | $152.09 | 2019-2021 | |
| Abbvie INC. | $139.10 | 2022-2023 | Ubrelvy |
| Chiesi USA, INC. | $121.15 | 2022-2023 | Cleviprex, Kengreal |
| Nevro Corp. | $107.27 | 2019-2022 | |
| Pfizer INC. | $92.85 | 2019-2023 | |
| Abbott Laboratories | $86.83 | 2021-2023 | Proclaim |
| Biodelivery Sciences International, INC. | $83.25 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.51 | 2019-2020 | |
| Nalu Medical, INC. | $58.69 | 2024 | Nalu Neurostimulation System |
| Tersera Therapeutics LLC | $36.90 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $30.77 | 2021 | |
| Vertos Medical, INC. | $28.54 | 2019-2021 | |
| Boston Scientific Corporation | $23.71 | 2019 | |
| Forte Bio-Pharma LLC | $22.83 | 2021 | |
| Indivior INC. | $22.09 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $19.88 | 2024 | |
| Si-Bone, INC. | $18.91 | 2024 | |
| Ermi LLC | $18.84 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.54 | 2020 | |
| Horizon Therapeutics Plc | $18.48 | 2019 | |
| Daiichi Sankyo INC. | $16.58 | 2019 | |
| Neuronetics, INC. | $15.14 | 2019 | |
| Vertiflex, INC. | $15.12 | 2019 | |
| Grt US Holding, INC. | $14.18 | 2020 | |
| Tenex Health INC. | $13.79 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.95 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hooman Behravan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.